Search bioRxiv⌕ Search

Biology subjects

Aschenbrenner, J. C.

Publications and source records attributed to Aschenbrenner, J. C..

7 recordsLinked to original sources

The first OpenBind release: An open experimental structure-affinity dataset and benchmark for structure-based AI

High-quality experimental datasets that link protein-ligand structures with binding affinity data are essential for developing and evaluating structure-based machine learning methods. To help address this need, we established OpenBind as an open-science initiative to generate large-scale experimental datasets for structure-based AI and molecular discovery. Here, we describe the first public OpenBind release, which, to the best of our knowledge, is the largest public single-target experimental structure-affinity dataset. The dataset focuses on enteroviral 2A protease, comprising 925 crystallographic binding events from 699 compounds and associated affinity measurements for 601 compounds. It combines structures from an initial fragment screen and follow-on molecules, together with affinity data, linking experimentally determined protein-ligand binding modes to biophysical measurements within a coherent antiviral discovery campaign. We used this dataset to evaluate protein-ligand structure prediction, binding-affinity prediction, and virtual screening using representative structure-based methods, including docking and cofolding. This exposed several challenges that are central to practical structure-based modelling: docking performance depends strongly on binding-pocket conformation, poses are difficult to rank, and structure-based affinity prediction remains challenging. Fine-tuning OpenFold3-p2 on the fragment-screen structures substantially improved pose prediction and virtual screening for related follow-on compounds, demonstrating how early-stage experimental structures can support target-specific model adaptation.

bioinformatics↗

Crystallographic fragment screening of the dengue virus polymerase reveals multiple binding sites for the development of non-nucleoside antiflavivirals

Dengue viruses (DENV) infect approximately 400 million people each year, and there are currently no effective therapeutics available. To explore potential starting points for antiviral drug development, we conducted a large-scale crystallographic fragment screen targeting the RNA-dependent RNA polymerase (RdRp) domain of the non-structural protein 5 (NS5) from DENV serotype 2. Our screening, which involved 1,108 fragments, identified 60 hit compounds across various known binding sites, including the active site, N pocket, and RNA tunnel. Additionally, we discovered a novel binding site and a fragment-binding hotspot in thumb site II. These structural findings open amenable avenues for developing non-nucleoside inhibitors and offer valuable insights for future structure-based drug design aimed at DENV and other flaviviral RdRps.

biophysics↗

Crystal structure of Fatty Acid Thioesterase A bound by 129 fragments provides diverse development opportunities

To alleviate the growing issue of herbicide resistance, diversification of the herbicide portfolio is necessary. A promising yet underutilised mode of action (MoA) are Fatty Acid Thioesterases (Fat), which terminate de novo fatty acid (FA) biosynthesis by releasing fatty acids from acyl carrier protein (ACP) cofactors. These enzymes impact plant growth and sterility by determining the amount and length of FAs present. To find novel chemical matter targeting this MoA we have solved the crystal structure of Arabidopsis thaliana FatA to 1.5[A] and conducted a crystallographic fragment screen which identified 141 hits. Our fragments recapitulated interactions made by current herbicides, but also targeted novel regions, namely the active site and the dimer interface. Ten fragments demonstrated on-scale potency, two of those exploiting different interactions to known herbicides. The screen also revealed large conformational changes exploited by some fragments, including stabilisation of a loop and shifts in the ACP-binding lid domain. These changes alter the accessibility of the substrate binding site by reducing the size of the apparent substrate access channel. Finally, the fragments readily lend themselves to designing compounds that both merge motifs and allow catalogue-based SAR exploration. Elaboration of one of the fragments resulted in an improvement of affinity from [~]20 M to [~]90nM KD. Thus our data may facilitate accelerated early discovery of alternative inhibitors that are novel in both chemical scaffolds and modes of interaction.

biochemistry↗

Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening

Chikungunya virus (CHIKV) causes severe fever, rash and debilitating joint pain that can last for months 1,2or even years. Millions of people have been infected with CHIKV, mostly in low and middle-income countries, and the virus continues to spread into new areas due to the geographical expansion of its mosquito hosts. Its genome encodes a macrodomain, which functions as an ADP-ribosyl hydrolase, removing ADPr from viral and host-cell proteins interfering with the innate immune response. Mutational studies have shown that the CHIKV nsP3 macrodomain is necessary for viral replication, making it a potential target for the development of antiviral therapeutics. We, therefore, performed a high-throughput crystallographic fragment screen against the CHIKV nsP3 macrodomain, yielding 109 fragment hits covering the ADPr-binding site and two adjacent subsites that are absent in the homologous macrodomain of SARS-CoV-2 but may be present in other alphaviruses, such as Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV). Finally, a subset of overlapping fragments was used to manually design three fragment merges covering the adenine and oxyanion subsites. The rich dataset of chemical matter and structural information discovered from this fragment screen is publicly available and can be used as a starting point for developing a CHIKV nsP3 macrodomain inhibitor.

biochemistry↗

Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response

A strategy for pandemic preparedness is the development of antivirals against a wide set of viral targets with complementary mechanisms of action. SARS-CoV-2 nsp3-mac1 is a viral macrodomain with ADP-ribosylhydrolase activity, which counteracts host immune response. Targeting the virus immunomodulatory functionality offers a differentiated strategy to inhibit SARS-CoV-2 compared to approved therapeutics, which target viral replication directly. Here we report a fragment-based lead generation campaign guided by computational approaches. We discover tool compounds which inhibit nsp3-mac1 activity at low nanomolar concentrations, and with responsive structure-activity relationships, high selectivity, and drug-like properties. Using our inhibitors, we show that inhibition of nsp3-mac1 increases ADP-ribosylation, but surprisingly does not translate to demonstrable antiviral activity in cell culture and iPSC-derived pneumocyte models. Further, no synergistic activity is observed in combination with interferon gamma, a main protease inhibitor, nor a papain-like protease inhibitor. Our results question the extent to which targeting modulation of innate immunity-driven ADP-ribosylation can influence SARS-CoV-2 replication. Moreover, these findings suggest that nsp3-mac1 might not be a suitable target for antiviral therapeutics development.

microbiology↗

High-throughput crystallographic fragment screening of Zika virus NS3 Helicase

The Zika virus (ZIKV), discovered in Africa in 1947, swiftly spread across continents, causing significant concern due to its recent association with microcephaly in newborns and Guillain-Barre syndrome in adults. Despite a decrease in prevalence, the potential for a resurgence remains, necessitating urgent therapeutic interventions. Like other flaviviruses, ZIKV presents promising drug targets within its replication machinery, notably the NS3 helicase (NS3Hel) protein, which plays critical roles in viral replication. However, a lack of structural information impedes the development of specific inhibitors targeting NS3Hel. Here we applied high-throughput crystallographic fragment screening on ZIKV NS3Hel, which yielded structures that reveal 3D binding poses of 46 fragments at multiple sites of the protein, including 11 unique fragments in the RNA-cleft site. These fragment structures provide templates for direct design of hit compounds and should thus assist the development of novel direct-acting antivirals against ZIKV and related flaviviruses, thus opening a promising avenue for combating future outbreaks.

biophysics↗

Crystallographic fragment screening delivers diverse chemical scaffolds for Zika virus NS2B-NS3 protease inhibitor development

The Zika viral protease NS2B-NS3 is essential for the cleavage of viral polyprotein precursor into individual structural and non-structural (NS) proteins and is therefore an attractive drug target. Generation of a robust crystal system of co-expressed NS2B-NS3 protease has enabled us to perform a crystallographic fragment screening campaign with 1076 fragments. 47 fragments with diverse scaffolds were identified to bind in the active site of the protease, with another 6 fragments observed in a potential allosteric site. To identify binding sites that are intolerant to mutation and thus suppress the outgrowth of viruses resistant to inhibitors developed from bound fragments, we performed deep mutational scanning of NS2B-NS3 protease. Merging fragment hits yields an extensive set of mergers, defined as synthetically accessible compounds that recapitulate constellations of observed fragment-protein interactions. In addition, the highly sociable fragment hits enable rapid exploration of chemical space via algorithmic calculation and thus yield diverse possible starting points that maximally explore the binding opportunities to NS2B-NS3 protease, facilitating its resistance-resilient antiviral development.

biochemistry↗